CRBP (Corbus Pharmaceuticals Holdings) EPS (Basic): $-5.82 (TTM As of Mar. 2026)

What is Corbus Pharmaceuticals Holdings EPS (Basic)?

Corbus Pharmaceuticals Holdings CRBP +0.80% 32 EPS (Basic) is $-5.82 as of Mar. 2026. GuruFocus rates CRBP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Corbus Pharmaceuticals Holdings's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-1.23. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.82.

Corbus Pharmaceuticals Holdings's EPS (Diluted) for the three months ended in Mar. 2026 was $-1.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.82.

Corbus Pharmaceuticals Holdings's EPS without NRI for the three months ended in Mar. 2026 was $-1.23. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -5.82.

During the past 3 years, the average EPS without NRI Growth Rate was 12.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 31.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Corbus Pharmaceuticals Holdings's highest 3-Year average EPS without NRI Growth Rate was 37.50% per year. The lowest was -175.80% per year. And the median was -8.40% per year.

Corbus Pharmaceuticals Holdings (NAS:CRBP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Corbus Pharmaceuticals Holdings EPS (Basic) Related Terms

Corbus Pharmaceuticals Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings EPS (Basic) Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-11.15

-10.15

-10.31

-3.68

-5.90

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-1.39	-1.44	-1.90	-1.25	-1.23

32GF Score

Corbus Pharmaceuticals Holdings Inc CRBP

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Corbus Pharmaceuticals Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Corbus Pharmaceuticals Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-78.537	-	0)	/	13.317
	=	-5.90

Corbus Pharmaceuticals Holdings's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-22.969	-	0)	/	18.707
	=	-1.23

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.82

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-5.82 mean?

Corbus Pharmaceuticals Holdings (CRBP) has a EPS (Basic) of $-5.82 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Corbus Pharmaceuticals Holdings and its competitors.

Is Corbus Pharmaceuticals Holdings' EPS (Basic) too high?

Corbus Pharmaceuticals Holdings' current EPS (Basic) is $-5.82. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Corbus Pharmaceuticals Holdings' EPS (Basic) compare to AGEN and HURA?

Corbus Pharmaceuticals Holdings' EPS (Basic) of $-5.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current EPS (Basic) is $-5.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Corbus Pharmaceuticals Holdings stock overvalued right now?

Corbus Pharmaceuticals Holdings (CRBP) has a current EPS (Basic) of $-5.82. The current EPS (Basic) is $-5.82. Corbus Pharmaceuticals Holdings' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (CRBP), the current EPS (Basic) is $-5.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies AGEN HURA SLNCF SPRB TTRX VXRT ANTX CNTB GNLX ACOG VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0SZI:UK 3371:Germany

Address 500 River Ridge Drive, Norwood, MA, USA, 02062

Website https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

32GF Score

Get the complete analysis for CRBP

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.24

Price

View CRBP Analysis

See EPS (Basic) data for all stocks →